Detalles de la búsqueda
1.
Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety.
Liver Cancer
; 12(2): 145-155, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37325487
2.
Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
Cancers (Basel)
; 15(23)2023 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38067235
3.
Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Thyroid
; 32(9): 1059-1068, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35950621
4.
Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
BMJ Open
; 10(3): e027665, 2020 03 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32220908
Resultados
1 -
4
de 4
1
Próxima >
>>